Liraglutide is a GLP-1 receptor agonist with a 13-hour half-life, requiring daily subcutaneous dosing. Approved for type 2 diabetes (Victoza 2010) and chronic weight management (Saxenda 2014, the first FDA-approved GLP-1 for weight loss). Notable for being the only GLP-1 with an FDA indication for adolescents aged 12 and older (Saxenda).
Drugs in this category
Related terms
- GLP-1
- Glucagon-like peptide-1 receptor agonist — class of drugs that mimic a gut hormone to reduce appetite and slow stomach emptying.
- Semaglutide
- GLP-1 receptor agonist; active ingredient in Wegovy, Ozempic, and Rybelsus.
- SCALE
- Pivotal trial of Saxenda (liraglutide 3.0 mg) for chronic weight management.